12-gene risk score endopredict (Myriad Genetics)
90
Structured Review
Myriad Genetics
12-gene risk score endopredict
12 Gene Risk Score Endopredict, supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/12-gene+risk+score+endopredict/12+gene+risk+score+endopredict/pmc11880448-96-27-31
Average 90 stars, based on 1 article reviews
12 Gene Risk Score Endopredict, supplied by Myriad Genetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/12-gene+risk+score+endopredict/12+gene+risk+score+endopredict/pmc11880448-96-27-31
Average 90 stars, based on 1 article reviews
12-gene risk score endopredict - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Cost-Utility Analysis of Multigene Assays to Guide Treatment Decisions for Node-Negative Early Breast Cancer. Article Snippet: Commercially available assays in the USA include the 21‐gene assay (the Oncotype DX Breast Recurrence Score test, Exact Sciences, Madison, US), 70‐gene assay (MammaPrint, Agendia, Amsterdam, Netherlands), Article Title: Cost–Utility Analysis of Multigene Assays to Guide Treatment Decisions for Node-Negative Early Breast Cancer Article Snippet: Commercially available assays in the USA include the 21-gene assay (the Oncotype DX Breast Recurrence Score test, Exact Sciences, Madison, US), 70-gene assay (MammaPrint, Agendia, Amsterdam, Netherlands), Adjuvant:Article Title: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary Article Snippet: TheAmericanSocietyofClinicalOncology (ASCO) has published evidence-based recommendations for practicing oncologists and other stakeholders on the appropriate use of results from assays of breast tumor biomarkers to guide or influence decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer.. Theclinicalpracticeguidelineaddresses two clinical questions.. For women with early-stage invasive breast cancer and with known estrogen receptor (ER)/ progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) status, which additional biomarkers have demonstrated clinical utility to guide decisions regarding the need for adjuvant systemic therapy and to guide the choice of specific drugs or regimens for adjuvant systemic therapy? |
